Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Royalty, Sino Biopharm, Theravance Biopharma - LARVOL DELTA

Late Breaking Abstract - Improvements in asthma symptom control with FF/UMEC/VI versus ICS/LABA usual care: Secondary outcomes from PERFORM, a pragmatic randomised controlled trial (ERS 2026) - P4 | "In patients with uncontrolled infrequently exacerbating asthma, FF/UMEC/VI improved asthma symptom control from baseline versus usual care ICS/LABA over 52 weeks. Funding GSK (219912/NCT06372496)"

Clinical • Late-breaking abstract • Asthma • Immunology • Respiratory Diseases

Achievability and durability of clinical remission with fluticasone furoate/umeclidinium/vilanterol in patients with asthma in the United States: A 24-month real-world analysis (ERS 2026) - "These real-world findings demonstrate the achievability and durability of CR with FF/UMEC/VI, and highlight the benefit of CR as a treatment goal to guide early intervention with FF/UMEC/VI. Funding GSK (219804)"

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

Predictive biomarkers for triple therapy response in COPD: a randomised controlled trial (ERS 2026) - "Aims and objectives Data on the clinical benefits of ICS/LAMA/LABA triple therapy (TT) in patients with mild-to-moderate COPD are limited...Patients were recruited from 44 hospitals in Japan and randomised (1:1) to receive either TT (FF/UMEC/VI) or dual therapy (DT: UMEC/VI) for 24 weeks...These findings highlight a potential pathway toward personalized therapy in COPD. Funding: GSK Supported Studies Programme (SCS #214161)."

Biomarker • Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases • CCL18 • CHI3L1 • POSTN

Comparative effects of triple inhaled therapy with budesonide/glycopyrronium/formoterol versus fluticasone furoate/umeclidinium/vilanterol on small airway disease in COPD patients: a randomized crossover study (ERS 2026) - "Both BGF and FUV improved small airway function and clinical symptoms. No significant differences in SAD parameters were observed between the two treatment regimens. These findings suggest comparable overall efficacy; however, larger and longer-term studies are needed to confirm potential differences in small airway effects."

Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Modelling predictive characteristics for disease stability in COPD: IMPACT post hoc analysis (ERS 2026) - P3 | " Using FF/UMEC/VI arm post hoc data from IMPACT (NCT02164513), Bayesian joint modelling with copula marginal regression was used to simultaneously model changes in CAT score, FEV1 (both normal) and number of exacerbations (negative binomial)... The probability of DS was affected by the degree of airflow limitation and exacerbation history; thus more patients may achieve DS if targeted earlier in the disease course. DS is achievable independent of CV risk factors or current symptom burden; therefore, DS should be considered a key treatment target in COPD for all patients. Funding: GSK (116855)"

Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Achievability of clinical remission in patients with asthma stepping up to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or initiating FF/UMEC/VI as initial maintenance therapy: Results of a real-world US study (ERS 2026) - "This real-world evidence suggests the benefit of early initiation of FF/UMEC/VI for achieving CR. Funding GSK (219804)"

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

Quality of life improvements with FF/UMEC/VI versus ICS/LABA usual care in patients with uncontrolled asthma: Secondary outcomes of PERFORM, a pragmatic randomised controlled trial (ERS 2026) - P4 | "Traditional randomised controlled trials (RCTs) have shown lung function and symptom improvements with ICS/LAMA/LABA versus ICS/LABA in moderate/severe asthma; however, evidence for QoL with triple versus dual therapy in routine practice is limited. Initiating FF/UMEC/VI improved patients' daily living, raising treatment expectations for early intervention in patients with symptomatic asthma and uncompromised lung function. Funding GSK (219912; NCT06372496)"

Clinical • HEOR • Asthma • Immunology • Respiratory Diseases

Impact of single-inhaler triple therapy FF/UMEC/VI on disease stability in copd: a real-world 12-month analysis (ERS 2026) - "In exacerbating COPD, once-daily FF/UMEC/VI improved physiology, symptoms and exacerbations, supporting its role in maintaining disease stability in high-risk patients; no unexpected safety signals emerged. Hyperinflation fell and gas transfer rose, suggesting overall functional improvements."

Clinical • Real-world • Real-world evidence • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL VS BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL IN COPD: A MULTINATIONAL PROPENSITY SCORE-MATCHED STUDY (CHEST 2026) - No abstract available

Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Is It Feasible to Assess Clinical Remission in Asthma via a Customized Data Extraction Approach from a Real-World Clinical Electronic Medical Records Database in Japan? A Retrospective Real-World Study. (PubMed, J Asthma) - " Data from the JAMDAS database were analyzed for patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy between August 18, 2020 and December 31, 2024...However, infrequent recording of CR components in clinical practice, particularly ACT and lung function tests, limits availability of EMR data for CR assessments and the potential generalizability of CR findings. Funding: GSK (Study 222904)."

Journal • Real-world evidence • Retrospective data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A multicentre, observational prospective study to characterise the use of inhaled triple therapy for COPD: TETRIS final results after a 24-month follow-up period. (PubMed, Ther Adv Respir Dis) - P | "At 24 months, the mean change in CAT sum score since baseline was -4.4 among patients on OD triple therapy (FF/UMEC/VI OD)...The steep drop at 24 months was mostly because only few patients remained under observation since the protocol permitted study completion at 18 months, and any patient who dropped out from the study was not censored but counted as patient no longer on continuous triple therapy. These findings support the effectiveness and stability of triple therapy in routine practice and highlight the value of OD single-inhaler regimens in optimising COPD management.Registrationhttps://clinicaltrials.gov/study/NCT04657211."

Journal • Observational data • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

COPD Stability and Asthma Remission: Different Words for the Same Therapeutic Ambition? (PubMed, Biomedicines) - "Evidence from optimized inhaled triple therapy, particularly with fluticasone furoate/umeclidinium/vilanterol, indicates that multidimensional stability can be achieved and maintained in a proportion of patients, while real-world studies reinforce its applicability beyond randomized trials...In addition, we propose a pragmatic multidimensional definition based on symptom stability, absence of moderate or severe exacerbations, no systemic corticosteroid use, and maintained lung function over 12 months. COPD stability should not be viewed as a weaker goal than asthma remission, but rather as the most appropriate COPD-specific expression of sustained low disease activity."

Journal • Review • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Total Ophthalmoplegia as an Early Manifestation of Herpes Zoster Ophthalmicus in an Elderly Patient With Asthma: A Case Report. (PubMed, Cureus) - "His only notable comorbidity was asthma, for which fluticasone furoate/umeclidinium/vilanterol had been prescribed, although he used it irregularly. The right eye was fixed, with total ptosis, absent spontaneous movement, and marked restriction in all gaze directions...The patient received intravenous acyclovir at 10 mg/kg every eight hours for 21 days, with daily renal function monitoring, as well as a short course of methylprednisolone and topical dermatologic and ophthalmologic therapies...Advanced age was the patient's major established risk factor, while asthma was his only chronic comorbidity. Asthma may represent a contributing clinical context, but a causal relationship with complicated HZO cannot be inferred from a single case."

Journal • Asthma • Cardiovascular • Diabetes • Herpes Zoster • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Ocular Inflammation • Oncology • Ophthalmology • Pain • Pulmonary Disease • Respiratory Diseases • Varicella Zoster

Treatable Traits-Oriented Management in Pre-COPD With Severe Obstructive Sleep Apnea: A Case Report of Symptomatic and Spirometric Improvement After Integrated Therapy. (PubMed, Respirol Case Rep) - "Integrated management with inhaled fluticasone furoate/umeclidinium/vilanterol and continuous positive airway pressure was initiated...Eosinophilic asthma was considered less likely because bronchodilator responsiveness was negative, blood eosinophils and total IgE were low, sputum eosinophils were negative, and sputum cytology showed neutrophilic inflammation. This case is hypothesis-generating and suggests that selected pre-COPD patients may benefit from multifactorial trait-oriented management."

Journal • Asthma • Cough • Immunology • Inflammation • Obstructive Sleep Apnea • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

Operational Highlights (PRNewswire) - "YUPELRI Collaboration Revenue increased 11% year-over-year, from $18.7 million to $20.7 million, driven by continued Net Sales growth and improved operating leverage...Q2 2026 TRELEGY net sales, reported by GSK, of approximately $1.0 billion; high confidence in achieving the $100 million 2026 milestone payment."

Sales • Asthma • Chronic Obstructive Pulmonary Disease • Immunology

Particle engineering, aerosol physics, and pulmonary deposition of single-inhaler triple ICS/LABA/LAMA therapies in obstructive airway diseases. (PubMed, Eur J Intern Med) - "Five device platforms are currently approved: two extrafine formulations delivering beclomethasone dipropionate/formoterol/glycopyrronium (the Modulite solution pressurised metered-dose inhaler [pMDI] and the NEXThaler breath-actuated dry powder inhaler [DPI]); the co-suspension pMDI Aerosphere platform (budesonide/glycopyrrolate/formoterol); the standard-particle Ellipta DPI (fluticasone furoate/umeclidinium/vilanterol); and the low-resistance, single-dose capsule-based DPI Breezhaler (mometasone furoate/indacaterol/glycopyrronium)...Rational device selection requires structured assessment of patient inspiratory capacity, disease phenotype, coordination, and adherence. Head-to-head scintigraphy and prospective imaging-outcome studies represent major evidence gaps."

Journal • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

MUST: 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Western University, Canada | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study. (PubMed, J Clin Med) - "We compared real-world clinical outcomes among adults with COPD receiving fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR)... In this large propensity score-matched real-world cohort study, patients receiving BUD/GLY/FOR experienced lower rates of COPD exacerbations and acute respiratory failure than those receiving FF/VI/UMEC. Because of the retrospective observational nature of the analysis, these findings should be considered hypothesis-generating and require confirmation in prospective comparative effectiveness studies."

Journal • Real-world evidence • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

General Medicines sales £2.3 billion (-9%); Trelegy £0.8 billion (-7%) (GSK Press Release)

Sales • Asthma • Chronic Obstructive Pulmonary Disease • Immunology

Clinical Remission with FF/UMEC/VI Versus ICS/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trial. (PubMed, Adv Ther) - P4 | "In a broad patient population with uncontrolled asthma, treatment with FF/UMEC/VI resulted in statistically significantly greater odds of achieving clinical remission versus usual care ICS/LABA in a setting reflecting routine practice, a secondary outcome of PERFORM. These findings were consistent irrespective of clinical remission definitions and provide evidence informing the use of FF/UMEC/VI in an underserved group of symptomatic patients with infrequent exacerbations and minimal lung function impairment."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Profiles and Disease Burden of Patients with COPD Initiating Triple Therapy in China. (PubMed, Int J Chron Obstruct Pulmon Dis) - "Index date was the first prescription for single-inhaler triple therapy (SITT; fluticasone furoate/umeclidinium/vilanterol or budesonide/glycopyrronium/formoterol fumarate) or multiple-inhaler triple therapy (MITT)...The high rates of COPD-related healthcare resource utilization and costs demonstrate the considerable burden of COPD in China, whilst the PDC results indicate medication adherence needs to be improved. These findings could help reduce the burden of COPD in China by supporting the planning and adjustment of patients' treatment strategies."

Journal • Observational data • Retrospective data • Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Hypertension • Immunology • Pulmonary Disease • Respiratory Diseases

GSK is expanding its partnership with Chia Tai Tianqing Pharmaceutical Group…by granting the company China commercialization rights for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; FF/UMEC/VI) and Anoro Ellipta (umeclidinium/vilanterol; UMEC/VI) (AllSci Corp) - "The agreement extends the companies’ May 2026 collaboration around the hepatitis B candidate bepirovirsen into respiratory medicine, creating a multi-product partnership spanning two therapeutic areas. Trelegy and Anoro generated combined global sales of GBP 3.54 billion (approximately USD 4.5 billion) in 2025. Financial terms were not disclosed. Under the agreement, CTTQ will purchase finished product from GSK and book China sales revenue, following the same commercialization and supply model used in the earlier bepirovirsen collaboration."

Licensing / partnership • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial. (PubMed, J Allergy Clin Immunol Glob) - "Addition of the long-acting muscarinic antagonist umeclidinium (UMEC) to the inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combination fluticasone furoate/vilanterol (FF/VI) improved lung function in adults with uncontrolled moderate to severe asthma in the CAPTAIN (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler) study; however, the impact on symptoms requires further investigation...The CAPTAIN study was a phase IIIA, randomized, controlled, 24- to 52-week study of patients with uncontrolled moderate to severe asthma despite ICS/LABA receiving once-daily single-inhaler FF/VI (100/25 or 200/25 μg) or FF/UMEC/VI (100/31.25/25, 100/62.5/25, 200/31.25/25, or 200/62.5/25 μg)...Similar trends were observed irrespective of type 2 status. Patients with symptomatic asthma may benefit from optimized treatment interventions, such as adding a long-acting muscarinic antagonist to ICS/LABA."

Journal • P1/2 data • P3 data • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Zymeworks to Acquire Theravance Biopharma, Inc. (GlobeNewswire) - "This acquisition, when closed, provides Zymeworks with access to a 35% U.S. net profit share in YUPELRI, the only approved nebulized LAMA for the maintenance treatment of COPD...Settlements have been reached with all YUPELRI generic filers for an April 2039 licensed launch date for their versions of the product, or earlier depending on certain circumstances...Theravance Biopharma remains eligible to receive an additional $125 million in commercial milestone payments from Viatri...Theravance Biopharma is expected to receive $100 million in commercial milestone payments from Royalty Pharma in Q1 2027 related to global net sales of TRELEGY ELLIPTA by GSK....Theravance Biopharma is eligible to receive up to ~20% royalty on net sales of VIBATIV from Cumberland."

Financing • M&A • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease

Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "FF/UMEC/VI was dominant over MITT in 5- and 10-year time horizons. Despite higher total costs due to increased drug acquisition, FF/UMEC/VI reduces healthcare resource utilization associated with COPD events, representing a cost-effective option compared to MITT for moderate to severe COPD in Chile."

HEOR • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases